How Much Does Zepbound Cost in District of Columbia in 2026?

Zepbound List Price and Retail Cost in DC

Eli Lilly sets Zepbound's wholesale acquisition cost at $1,059.87 per four-week supply, a figure that applies uniformly across all available doses from 2.5 mg through 15 mg [1]. Because DC has no statewide drug-pricing cap for non-Medicaid prescriptions, the average cash-pay price at retail pharmacies in Washington mirrors the list price at $1,059 per month.

That number represents the sticker price before any discounts. Most residents will not pay it. Pharmacy benefit managers negotiate net prices with Lilly, and the actual amount a patient owes depends on formulary tier, plan design, and whether a manufacturer coupon applies. The FDA-approved prescribing information confirms tirzepatide is available only by prescription [2], so patients cannot bypass insurer formularies by purchasing it over the counter.

For context, tirzepatide's cost sits in line with other branded incretin therapies. Novo Nordisk's semaglutide 2.4 mg (Wegovy) also carries a list price above $1,000 monthly [3]. The real differentiator for DC residents is which plan they carry and whether they qualify for Lilly's direct savings programs.

Insurance Coverage for Zepbound in DC

Most major commercial insurers operating in the District now include Zepbound on their formularies, typically at a specialty or non-preferred brand tier. Plans offered through DC Health Link, the District's Affordable Care Act marketplace, vary by carrier. CareFirst BlueCross BlueShield and Kaiser Permanente of the Mid-Atlantic, the two largest marketplace insurers in DC, each maintain prior authorization requirements before approving tirzepatide for weight management [4].

Prior authorization criteria generally follow the FDA label: a body mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia [2]. Some plans add a step-therapy requirement, asking patients to document a trial of lifestyle modification or a lower-cost agent first.

Self-insured employer plans, which cover a large share of DC's federal workforce, set their own formulary rules. The Federal Employees Health Benefits (FEHB) program has expanded anti-obesity medication coverage for the 2026 plan year, though individual FEHB carriers may still impose quantity limits or require documentation of a 5% weight-loss target at 12 weeks [5]. Residents should request a formulary exception letter from their prescriber if an initial denial occurs, citing SURMOUNT trial data showing clinically meaningful weight reduction [6].

DC Medicaid Coverage

District of Columbia Medicaid, administered through the DC Department of Health Care Finance, covers Zepbound with prior authorization. DC is one of a growing number of jurisdictions that include GLP-1 receptor agonists for chronic weight management on the Medicaid preferred drug list [7].

To obtain approval, prescribers must submit documentation confirming the patient's BMI, at least one weight-related comorbidity, and participation in a concurrent lifestyle intervention. The Obesity Medicine Association's 2024 clinical practice statement recommends anti-obesity pharmacotherapy as an adjunct to nutritional counseling and physical activity, not as a standalone treatment [8]. DC Medicaid's criteria align with this guidance.

Dual-eligible beneficiaries (those enrolled in both Medicare and Medicaid) face a different situation. Traditional Medicare Part D does not yet cover anti-obesity medications, although legislative proposals to change this remain active in Congress [9]. Dual-eligible residents in DC should confirm with their Medicaid managed care organization whether Medicaid will serve as the primary payer for Zepbound.

The Eli Lilly Savings Card

Lilly's Zepbound Savings Card program is available to commercially insured residents of the District of Columbia. Eligible patients pay as little as $25 per month for up to 12 fills, with Lilly covering the remaining cost up to a program maximum [10].

Eligibility rules exclude patients covered by government-funded programs: Medicare, Medicaid, TRICARE, and VA benefits. This restriction follows the federal Anti-Kickback Statute, which prohibits manufacturer copay assistance for federally funded beneficiaries [11]. FEHB enrollees should check with Lilly's program terms, as FEHB plans are sometimes classified differently from standard commercial coverage.

Patients activate the card at zepbound.lilly.com and present it at the pharmacy alongside their insurance card. The savings card functions as a secondary payer, reducing the patient's copay or coinsurance after the primary insurer processes the claim. If the primary insurer denies the claim entirely, the card will not apply, and the patient would need to appeal the denial or explore other options.

Compounded Tirzepatide in DC

Compounded tirzepatide is available in the District of Columbia through licensed 503A compounding pharmacies. These pharmacies operate under the federal Drug Quality and Security Act (DQSA) and must compound patient-specific prescriptions based on a valid prescriber order [12].

The average cost runs approximately $249 per month. That is roughly 76% less than the brand-name list price.

A critical distinction: the FDA has stated that tirzepatide is not on the drug shortage list as of early 2025, and compounding of commercially available drugs when no shortage exists raises regulatory questions under Section 503A of the Federal Food, Drug, and Cosmetic Act [12]. Patients considering compounded tirzepatide should verify that their pharmacy holds a current DC Board of Pharmacy compounding license and that the prescription originates from a licensed prescriber who has conducted an appropriate medical evaluation.

Compounded formulations are not FDA-approved products. They do not undergo the same bioequivalence testing as branded Zepbound [13]. The Endocrine Society's 2024 position statement on anti-obesity medications notes that patients using non-FDA-approved formulations should receive additional monitoring, including injection-site assessments and periodic HbA1c checks, to confirm therapeutic response [14].

Telehealth Prescribing in DC

DC permits telehealth prescribing of Zepbound. The District's telehealth parity law, updated in 2021, requires insurers to cover telehealth-delivered services at the same rate as in-person visits [15]. This means a weight-management consultation conducted via video counts as a covered medical visit for the purpose of initiating or refilling a Zepbound prescription.

Prescribers must hold a DC medical license or practice under the Interstate Medical Licensure Compact, which DC joined. The Ryan Haight Act requires a valid patient-prescriber relationship before prescribing controlled substances via telehealth, but tirzepatide is not a scheduled controlled substance, so this requirement does not apply [2].

Several national telehealth platforms now operate in DC and can prescribe Zepbound with shipment from a licensed pharmacy. Patients should confirm that the platform's prescriber is DC-licensed and that the dispensing pharmacy is registered with the DC Board of Pharmacy.

How Much Weight Does Zepbound Produce?

The SURMOUNT-1 trial (N=2,539) randomized adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one comorbidity to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo. At 72 weeks, mean body weight reductions were 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) compared with 3.1% for placebo [6]. Over one-third of participants on the 15 mg dose lost more than 25% of their body weight.

These results exceeded those of semaglutide 2.4 mg in the STEP-1 trial (N=1,961), which showed 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [16]. Head-to-head data from the SURMOUNT-5 trial further confirmed tirzepatide's superiority over semaglutide for weight reduction [17].

For DC residents weighing the cost-benefit calculation, the clinical magnitude matters. The American Heart Association's 2023 obesity guideline recognizes that 10% or greater weight loss can produce meaningful improvements in blood pressure, lipid levels, and glycemic control [18]. Tirzepatide's dual GIP/GLP-1 mechanism, which targets both the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, appears to drive greater weight loss than GLP-1-only agents [6].

Practical Ways to Lower Your Zepbound Cost in DC

Paying full price is rarely the only option. DC residents have several concrete paths to reduce out-of-pocket spending.

Use the Lilly Savings Card first. For commercially insured patients, this is the single most effective cost-reduction tool, potentially dropping the monthly cost to $25 [10].

Request a formulary exception. If your insurer places Zepbound on a high tier or excludes it, your prescriber can submit a letter of medical necessity citing SURMOUNT-1 outcomes and the FDA-approved indication [2][6]. DC insurance regulations require insurers to respond to exception requests within 72 hours for standard requests and 24 hours for expedited requests.

Compare pharmacy prices. DC retail pharmacies may offer slightly different cash prices depending on their purchasing agreements. GoodRx and RxSaver aggregate pricing data across local pharmacies, and prices can vary by $50 to $100 between locations.

Ask about compounded tirzepatide. At $249 per month, compounded formulations cost a fraction of the branded product. Confirm the pharmacy's 503A license and discuss the trade-offs of a non-FDA-approved product with your prescriber [12][13].

Check Lilly's direct-to-patient programs. Eli Lilly launched LillyDirect, a direct-to-patient platform offering certain medications with home delivery and transparent pricing. DC residents can check eligibility through the platform [10].

Dose Escalation and Total Annual Cost

Zepbound's prescribing information specifies a structured dose-escalation schedule: 2.5 mg weekly for four weeks, then 5 mg weekly [2]. The dose can increase in 2.5 mg increments every four weeks to a maximum of 15 mg weekly, based on tolerability and clinical response.

Because Eli Lilly prices every dose pen identically at $1,059 per month, the total annual list-price exposure is $12,708 regardless of dose [1]. This flat pricing structure differs from some other injectable medications where higher doses cost more. For insured patients, the annual out-of-pocket maximum set by their plan caps total spending. Under ACA-compliant plans sold through DC Health Link, the 2026 out-of-pocket maximum is $9,200 for an individual [4].

Common side effects during dose escalation include nausea (reported in 24% to 33% of SURMOUNT-1 participants on active drug), diarrhea, and decreased appetite [6]. These effects were mostly mild to moderate and tended to diminish after the first eight to twelve weeks of treatment. Prescribers in DC should counsel patients to expect transient GI symptoms and to avoid rapid dose increases outside the labeled schedule.

Who Should Not Take Zepbound

Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors, based on findings in rodent studies [2]. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The FDA label also lists a history of serious hypersensitivity to tirzepatide or any excipient as a contraindication [2].

Patients with a history of pancreatitis should use tirzepatide with caution. The SURMOUNT-1 trial reported acute pancreatitis in <0.2% of participants on active drug, but the prescribing information recommends discontinuation if pancreatitis is suspected [6][2]. The American Gastroenterological Association's 2024 guideline on anti-obesity medications recommends baseline lipase measurement before initiating incretin-based therapies in patients with prior pancreatitis [19].